Treatment of Androgenetic Alopecia in Females, 12 Beam

NCT ID: NCT01016964

Last Updated: 2012-09-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 12 beam model for androgenetic alopecia in females when treatment is applied as directed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized double-blind, sham controlled clinical study, evaluating changes in terminal hair count in the evaluation zone having evidence of androgenetic alopecia (miniaturized hair).

The trial with 63 female subjects, who have been diagnosed with androgenetic alopecia, who are between 25 and 60 years of age, have Fitzpatrick Skin Types I-IV, with classifications of Ludwig I-4, II-1, II-2, or frontal, have active hair loss within the last 12 months.

Subjects will use the device on three non-concurring days a week as directed per device for 26 weeks duration.

Initial efficacy endpoint for each subject will be assessed at visit 4 (week 16).

Safety analysis will be assessed based on the reports of adverse events during study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Androgenetic Alopecia Hair Loss Female Pattern Baldness

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Androgenetic Alopecia Hair Loss Female Pattern Baldness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sham Device

Sham device

Group Type SHAM_COMPARATOR

Sham Device

Intervention Type DEVICE

Sham Device

LLT Device 2009 12 Beams

HairMax LaserComb 2009 model 12 beam

Group Type ACTIVE_COMPARATOR

HairMax LaserComb 2009 model 12 beam

Intervention Type DEVICE

HairMax LaserComb

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HairMax LaserComb 2009 model 12 beam

HairMax LaserComb

Intervention Type DEVICE

Sham Device

Sham Device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of androgenetic alopecia
* Fitzpatrick Skin types I-IV
* Ludwig I-4, II-1, II-2, or frontal
* Active hair loss within last 12 months

Exclusion Criteria

* Photosensitivity to laser light
* Malignancy in the target area
* Pregnancy
* Lactating females
Minimum Eligible Age

25 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lexington International, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maria Hordinsky, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota

Wilma Bergfeld, M.D.

Role: PRINCIPAL_INVESTIGATOR

The Cleveland Clinic

Lawrence Schachner, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Miami

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Miami Miller School of Medicine - Dermatology

Miami, Florida, United States

Site Status

University of Minnesota, Department of Dermatology

Minneapolis, Minnesota, United States

Site Status

Cleveland Clinic Foundation - Department of Dermatology

Cleveland, Ohio, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Investig. 2009;29(5):283-92. doi: 10.2165/00044011-200929050-00001.

Reference Type BACKGROUND
PMID: 19366270 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12 2009-F-02

Identifier Type: -

Identifier Source: org_study_id

NCT01042756

Identifier Type: -

Identifier Source: nct_alias